• Home
  • About Modra
    • Overview
    • Management Team
    • Supervisory Board
  • Technology
    • Oral Taxane Therapy
    • Patient Benefit
    • Publications
  • Pipeline
    • Overview
    • ModraDoc006/r
    • ModraPac005/r
    • Partnerships
  • Careers
  • News
    • Press Releases
    • Presentations
    • Events
  • Contact
Dizy-Logo

  • Modra Pharmaceuticals Appoints Two New Supervisory Board Members Adding Significant Experience in Corporate and Clinical Development

    27 April, 2021

  • Modra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting

    12 February, 2021

  • ModraDoc006/Ritonavir Offers Promising Therapeutic Option for mCRPC

    11 February, 2021

Follow Us

Modra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting

...

ModraDoc006/Ritonavir Offers Promising Therapeutic Option for mCRPC

11 February 2021 ModraDoc006/Ritonavir Offers Promising Therapeutic Option for mCRPC, Convenient Approach Amid COVID-19 Pandemic Article published in ...

Modra Pharmaceuticals Announces First Patients Treated in Phase IIb Metastatic Prostate Cancer Trial

14 august 2019 –Study will test efficacy and tolerability of novel docetaxel-based oral chemotherapeutic ModraDoc006/r–   Amsterdam A...

Contact
Modra Pharmaceuticals B.V.
Barbara Strozzilaan 201
1083 HN Amsterdam
The Netherlands
Phone: +31 (0)20-205 0188
E-mail: info@modrapharmaceuticals.com
Info
  • Privacy Policy